Introduction
The measurement of circulating biomarkers is useful in the diagnosis and management of heart failure (HF), and the most established biomarkers are the natriuretic peptides, N-terminal pro-brain natriuretic peptide (NT-proBNP) and B-type natriuretic peptide. 1 Accumulating evidence indicates that circulating cardiac troponin is powerfully prognostic for adverse events in HF. 2 The introduction of high-sensitivity (hs) assays has allowed the accurate detection of very low levels of circulating cardiac troponins in stable HF. 3 We previously showed, using an hs troponin T (TnT) assay, that levels of circulating TnT were elevated in stable HF patients with both reduced and preserved ejection fraction (HFrEF and HFpEF, respectively) compared with community-based controls. 4 Recently, an hs assay for troponin I (hsTnI) has been developed and shown to provide independent diagnostic and prognostic information compared with hsTnT in the settings of acute and chronic coronary disease. 5, 6 Comparisons of TnI vs. TnT levels in coronary disease have revealed differences in troponin release patterns in response to ischaemia, 7 as well as sex differences of potential clinical significance. 8 In contrast, little is known about the relative levels of TnI vs. TnT in HF or about the differences in their predictive capabilities for secondary events in HF.
Accordingly, our aims were, firstly, to assess the clinical correlates and prognostic value of circulating TnI measured using an hs assay in a large unselected cohort of patients with stable HF and to compare these findings with those obtained using an hs assay for TnT. Secondly, recognizing that HF has been categorized into different phenotypes including the male-predominant HFrEF (largely related to coronary disease) and the female-predominant HFpEF (largely related to hypertension), we aimed to compare TnI and TnT levels and the prognostic performances of the hsTnI and hsTnT assays between these groups. We were also interested in comparing TnI and TnT levels and risk profiles in the recently introduced third category of HF with mid-range ejection fraction (HFmrEF) subgroup. Furthermore, on the basis of prior reports on sex differences in hsTnI in coronary disease, we assessed whether sex differences in the predictive value of circulating troponins were present in HF.
Methods

Study population
Patients were enrolled from the six major public institutions across the island of Singapore as part of the Singapore Heart Failure Outcomes and Phenotypes (SHOP) cohort study. 9 Eligibility criteria included a primary diagnosis of HF at hospital admission or attendance at a hospital clinic for management within 6 months of an episode of acute decompensation. A cardiologist who was blinded to biomarker measurements made the diagnosis of HF, validated by European Society of Cardiology (ESC) criteria. 1 Patients with HF secondary to a primary diagnosis of acute coronary syndrome or secondary to severe valvular disease or infiltrative diseases were excluded, as were those with end-stage renal failure (defined as an estimated glomerular filtration rate of <15 mL/min/1.73 m 2 ). Importantly, patients were recruited after in-hospital stabilization just prior to discharge, or in outpatient settings, thus ensuring that all patients were sampled whilst clinically compensated. Therefore, this cohort represents a stable or compensated HF population as opposed to a decompensated HF population secondary to an acute event. The study protocol was approved by the ethics committees of each of the participating institutions and all participants gave informed consent.
Procedures
Baseline assessment included the acquisition of medical history, physical examination, resting 12-lead electrocardiography, blood sampling and transthoracic Doppler echocardiography using standardized equipment (Vivid Ultrasound System; General Electric Healthcare, Milwaukee, WI, USA) and in compliance with the recommendations of the American Society of Echocardiography. 10 The presence or absence of coronary artery disease (CAD) was confirmed by previous angiogram reports available from hospital records. The biplane method of discs was used to measure left ventricular ejection fraction (LVEF). According to baseline LVEF, patients were subsequently stratified into HFrEF (LVEF <50%) and HFpEF (LVEF ≥50%) subgroups. All patients diagnosed with HFpEF satisfied both the diagnostic criteria defined by the ESC guidelines 1 and those published by Paulus et al. 11 Patients with missing data for LVEF (n = 3) were excluded from the analyses. All participants were followed for the clinical outcome, defined as a composite endpoint of all-cause mortality or first rehospitalization for HF. Medical records were checked for readmissions for follow-up events.
Biomarker assays
Plasma NT-proBNP and hsTnT were measured by electrochemiluminescence immunoassays on a Cobas immunoanalyser (Roche Diagnostics GmbH, Mannheim, Germany). The measurement ranges of the NT-proBNP and hsTnT assays were 5-35 000 pg/mL and 3-10 000 pg/mL, respectively, defined by the limit of blank. The established laboratory mean concentrations and inter-assay coefficient of variation (CV) of low-quality (NT-proBNP, 141 pg/mL, 3.38%; hsTnT, 26.7 pg/mL, 6.66%) and high-quality (NT-proBNP, 4759 pg/mL, 4.03%; hsTnT, 2090 pg/mL, 4.06%) control samples were derived from 56 independent runs. The limits of detection and blank for the hsTnT assay were 4.72 pg/mL and 2.16 pg/mL, respectively. In the hsTnI assay, concentrations were measured by chemiluminescent microparticle immunoassay (ARCHITECT STAT High-Sensitivity Troponin-I assay) using the ARCHITECT i2000SR System (Diagnostic Division, Abbott Ireland Ltd, Longford, Ireland). The calibration range of the hsTnI assay was 0-50 000 pg/mL and the limit of detection was 1.2 pg/mL.
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The ranges of the limits of detection and blank were 1.1-1.9 pg/mL and 0.7-1.3 pg/mL, respectively. The in-house laboratory mean and inter-assay CV of the low-(21.4 pg/mL; 4.92%), medium-(195 pg/mL; 3.55%) and high-(15 505 pg/mL; 2.84%) quality controls were established from 20 independent runs. cardiovascular risk factors were independently correlated with each biomarker for each HF group. The relationships of each hs troponin assay with the composite outcome of all-cause mortality or first rehospitalization for HF were examined univariably using Kaplan-Meier survival analyses and multivariably using Cox regression models adjusting for previously selected a priori covariates. The covariates used were age, sex, body mass index (BMI), smoking status, New York Heart Association (NYHA) class, history of diabetes, CAD, history of atrial fibrillation (AF), beta-blocker therapy, creatinine and systolic blood pressure (SBP). All hazard ratios (HRs) and beta values are presented as a 1-standard deviation (SD) unit increase in the log-transformed 'Biomarker'. The relationship between each hs troponin assay with the composite outcome was first analysed in the total population and then (HFrEF, LVEF <50%; HFpEF, LVEF ≥50%). A sub-analysis was performed incorporating the third, newly categorized HF group (HFrEF, LVEF < 40%; HFmrEF, LVEF ≥40% and <50%; HFpEF, LVEF ≥50%).
Areas under receiver operating characteristic (ROC) curves (AUCs) were ascertained in order to assess the unadjusted predictive power for the composite endpoint. To determine the additional prognostic values of hsTnI and hsTnT on top of a clinical base model, compared with the performance of NT-proBNP, further AUCs were analysed and the continuous net reclassification index (cNRI) and integrated discrimination improvement index (IDI) were ascertained using the survIDINRI package in R. 14, 15 We performed sensitivity analyses to assess the robustness of our findings. The analyses between each hs troponin assay and the composite outcome were repeated with the population stratified into two groups depending on the method of enrolment into the study. These two groups included those who were recruited just prior to discharge from hospital (inpatient) and those who were recruited within 6 months post-acute admission in an outpatient setting (outpatient).
A second sensitivity analysis was performed analysing both outcomes (all-cause mortality and first HF rehospitalization) separately.
Results
Baseline characteristics and clinical correlates of high-sensitivity troponin I and troponin T
Baseline characteristics of patients stratified by the two main HF types are displayed in Table 1 . Within a total of 1096 patients, 853 (77.8%) had HFrEF and 829 (75.6%) were men. Patients with HFpEF (n = 243) were older, more likely to be female, had a higher BMI, were less likely to be smokers and had lower haemoglobin concentrations. They were also more likely to be hypertensive, but less likely to be on beta-blocker, ACE-inhibitor or diuretic therapy. Patients with HFrEF were more likely to have a history of CAD. Patient characteristics in the HFmrEF group compared with the HFrEF and HFpEF groups can be viewed in the supplementary material online , Table S1 . The risk factor profile of the HFmrEF group fell between and showed equal levels of similarity to those of the HFrEF and HFpEF groups.
Circulating hsTnI, hsTnT and NT-proBNP levels were higher in HFrEF patients than in HFpEF and HFmrEF patients (Figure 1) . The expected strong correlation between hsTnI and hsTnT (r = 0.757, P < 0.001) was observed for the total population.
Characteristics of patients stratified by median hs troponin level can be viewed in the supplementary material online, Table S2 . Patients with a TnI concentration above the median were more likely to be male, have a higher BMI, poorer LVEF, a history of CAD and poorer renal function. Patients with a TnT concentration above the median level were more likely to be older, male, have a lower LVEF, a history of CAD, hypertension or diabetes and to be taking beta-blocker therapy and to have poorer renal function.
In multivariable linear regression analyses, age was the only risk factor showing independent associations with hsTnI in all three subgroups ( Table 2) ; however, it was independently associated with hsTnT only in HFpEF patients. No other risk factors showed similar significant independent correlations across the three HF subtypes in either of the troponin assays.
Associations of high-sensitivity troponin I and troponin T with mortality or heart failure readmission in the total cohort 
Figure 1
Comparisons between biomarker levels and heart failure type and sex. HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hs, high-sensitivity; Ln, natural logarithm; NT-proBNP, N-terminal pro-brain natriuretic peptide; TnI, troponin I; TnT, troponin T.
Increasing hsTnI levels were associated with the composite event rate in the total cohort in a multivariable model adjusted for age, sex, BMI, smoking status, NYHA class, diabetes, CAD, AF, beta-blocker therapy, creatinine and SBP (HR 1.36, 95% CI 1.24-1.45; P < 0.001 per SD increase in hsTnI) and remained significant when NT-proBNP was introduced into the model (HR 1.24, 95% CI 1.12-1.37; P < 0.001). An elevated hsTnT level was also associated with a significant risk for the composite endpoint in a multivariable model (HR 1.48, 95% CI 1.33-1.64; P < 0.001 per SD increase in hsTnT). Again, this association remained significant 
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Beta estimate (95% with the addition of NT-proBNP (HR 1.33, 95% CI 1.18-1.59; P < 0.001 per SD increase in hsTnT). The two hs troponin assays predicted outcome equally well in men and women within the total cohort (no sex interaction). AUC, area under the curve; CI, confidence interval; NT-proBNP, N-terminal pro-brain natriuretic peptide. The clinical model is made up of only the clinical variables: age, sex, body mass index, smoking status, New York Heart Association class, diabetes, coronary artery disease, atrial fibrillation, beta-blocker therapy, creatinine and systolic blood pressure. The subsequent models are the clinical models with the addition of NT-proBNP, hsTnI or hsTnT for the total cohort and for each heart failure subgroup. AUCs in bold indicate a significant difference between the clinical model and the clinical model with the addition of the biomarker. The optimal cut-off value corresponds to the troponin level at which the sum of sensitivity and specificity is greatest.
Associations of high-sensitivity troponin I and troponin T with composite events in heart failure with reduced and preserved ejection fraction
In the sub-analysis that included HFmrEF in the categorization of HF, both high plasma hsTnI and hsTnT were associated with a higher composite event rate in HFmrEF in univariable models (supplementary material online, Figure S1 ). However, neither troponin assay was significantly associated with composite events in HFmrEF in a multivariable model [hsTnI: HR 1.25, 95% CI 0.84-1.84 (P = 0.27 per SD increase in hsTnI); hsTnT: HR 1.45, 95% CI 0.89-2.37 (P = 0.14 per SD increase in hsTnT)].
Given the known higher prevalence of HFpEF in women, also seen in this study, and the previously found sex difference between troponin assays, interactions between troponin level and sex were tested in each HF type. The only significant sex interaction found was for hsTnI in HFpEF (sex interaction, P =0.03). In HFpEF, hsTnI was a stronger predictor for composite events in men than in women in a multivariable model [men: HR 3.33, 95% CI 1.82-6.09 (P < 0.001 per SD increase in hsTnI); women: HR 1.35, 95% CI 0.94-1.93 (P = 0.10 per SD increase in hsTnI)] (supplementary material online, Figure S2 ). There were no significant sex interactions for hsTnI and hsTnT in HFrEF.
From ROC analysis, we determined optimal cut-off values of hsTnI and hsTnT for the prediction of the composite endpoint in the overall cohort, and separately by HF type ( Table 3) . Both plasma hsTnI and hsTnT added significant value to the clinical model in the total cohort, in HFrEF and in HFpEF patients. The AUC was greater in HFpEF patients than in HFrEF patients for both hs troponin assays. Interestingly, when added individually, both troponin assays led to a significant improvement in predictive capability in HFpEF patients in comparison with the addition of NT-proBNP to the clinical model, which did not provide any significant improvement.
. Finally, we determined the cNRI and IDI with the addition of hsTnI and hsTnT to a base model containing age, sex, BMI, smoking status, NYHA class, diabetes, CAD, AF, beta-blocker therapy, creatinine and SBP. The same analyses were repeated with the addition of NT-proBNP to the model for comparison purposes. Both assays added significant value to the clinical base model in the total cohort, and in HFrEF and HFpEF patients ( Table 4) . Both cNRI and IDI were greater in HFpEF patients than in HFrEF patients. Interestingly, once again hsTnT provided the greatest additional value when added to the base model in HFpEF patients, especially in comparison with NT-proBNP, which offered no significant value in terms of cNRI and IDI.
Sensitivity analysis
Overall, 32.7% of participants were enrolled from the outpatient setting; this included 32.0% of the HFpEF group and 32.9% of the HFrEF group. There were no significant interactions between the hs troponin assay and type of enrolment in the total population or in the HFrEF population. Both troponin assays were independently predictive of composite outcomes in both enrolment groups in the total population and also when analysed in the HFrEF subgroup (data not shown). These analyses were not repeated in the HFpEF subgroup because its numbers were limited.
Both hsTnI and hsTnT were significantly associated with the single outcome of all-cause mortality in the total population in Table 4 Continuous net reclassification index (cNRI) and integrated discrimination improvement index (IDI) of the additional value of high-sensitivity troponin I (hsTnI) and troponin T (hsTnT) to the clinical characteristics for the total cohort, and for patients with heart failure with reduced (HFrEF) and preserved (HFpEF) ejection fraction the multivariable models with and without NT-proBNP, and also in the HFrEF group. This analysis was not repeated in the HFpEF group, again in view of the limited number of events (19 for hsTnI and 18 for hsTnT). Results obtained for HF readmission as the outcome mirrored those of the main analyses (data not shown) and also did so when stratified into HFrEF and HFpEF groups. As with the main analysis, hsTnI showed a stronger association with HF readmission in men with HFpEF than in women with HFpEF (interaction between hsTnI and sex, P =0.02).
Discussion
We report the first comparison of hs cardiac troponin T and troponin I levels, both exquisitely sensitive markers of myocyte injury, in a well-characterized chronic HF cohort. The prognostic performances of both assays are presented for the overall cohort and by ventricular phenotype. The HFmrEF phenotype has recently been created as a new HF category encompassing the 'grey' area of HF patients presenting with an LVEF of ≥40% and <50%. 1 The categorization of patients into different HF groups is vital as underlying pathophysiology, associated comorbidities and responses to therapies differ between the groups. Troponin levels in HFmrEF fall between those observed in HFrEF and HFpEF, and HFmrEF patients share risk factor profiles similar to those of both HFrEF and HFpEF patients. This suggests that HFmrEF is a composite syndrome that shares aspects of its pathophysiology with both HFpEF and HFrEF.
Both cardiac troponin I and T plasma concentrations, measured by well-validated hs assays, were elevated above normal in all three HF categories. Both troponin concentrations were independently associated with cardiovascular risk factors known to affect the individual HF phenotypes. However, troponins T and I were not independently associated with the same risk factors across all three HF phenotypes. This highlights the complexity of the HF . syndrome and may reflect differences in the biology of troponin release, as well as in the pathophysiology underpinning the different HF phenotypes. In addition, differences in sample size across the three categories may have obscured relationships, especially in the smaller HFmrEF group. In the total study population, both troponins were independently associated with a poorer outcome in terms of the composite endpoint of all-cause mortality or first rehospitalization for HF. Both assays were also able to predict the composite endpoint of death or readmission with decompensated HF in HFpEF better than in HFrEF. HFpEF comprises a large subgroup of HF. 16 It is associated with comorbidities such as diabetes mellitus and hypertension, which foster systemic inflammation resulting in endothelial dysfunction with consequent associated adverse pro-coagulant and vasoconstrictor effects. 17 The current findings show that both assays are independently associated with increasing age and hsTnT is associated with diabetes in HFpEF patients, both of which are risk factors typically seen in HFpEF and also known to involve endothelial dysfunction. 17 Both assays showed greater improvements in predictive value in terms of AUC, cNRI and IDI values in HFpEF than in HFrEF. However, the greatest improvement was seen with hsTnT in HFpEF, which suggests that hsTnT is more sensitive in HFpEF as a prognostic marker.
Current guidelines recommend the use of NT-proBNP in the diagnosis, prognosis and management of HF.
1 Studies have confirmed the importance of NT-proBNP as a diagnostic biomarker in patients with acute decompensated HF with or without preserved LVEF. 4 However, in HFpEF, natriuretic peptide levels can be normal (or at least well below the diagnostic thresholds employed in emergency departments for assessing acutely symptomatic patients), especially in the incipient and treated phases of the syndrome. We show that NT-proBNP does not offer added prognostic value to our clinical model in HFpEF as hsTnI and hsTnT do. Cardiac troponins are routinely used in the diagnosis and management of acute coronary syndromes. Their well-documented prognostic power in HF has been acknowledged in recent authoritative guidelines. 18 A recent study showed that elevated TnI and TnT were associated with poorer outcomes in patients hospitalized for decompensated HF. 19 However, to our knowledge, there have been no prior studies comparing hs assays, particularly for troponins T and I, in the prediction of adverse cardiovascular events in undifferentiated HF or in HFrEF compared with HFpEF. In keeping with the current results, hsTnT has been previously reported as higher in HF patients than in controls and higher in HFrEF than in HFpEF. 4 Interestingly, we found both hsTnT and hsTnI to be more predictive of a poorer outcome in HFpEF patients than in HFrEF patients. This is counter-intuitive, given that troponins are more disturbed in HFrEF than in HFpEF. In addition, ischaemic aetiology of HF is less common in HFpEF than in HFrEF, although troponins are the prime markers of ischaemic myocyte necrosis. Elevated troponin may therefore reflect cardiac cell loss secondary to chronic inflammation or other, as yet unknown, non-ischaemic pathologies in HFpEF and hence these results should be interpreted with caution.
Plasma concentrations of cardiac troponins are known to be higher in men than in women within the general population, although the underlying factors responsible for the presence of, and gender differences in, circulating troponins in apparently healthy individuals remain obscure. 20 HFpEF is known to have a higher prevalence in women compared with men, occurring at a ratio of 2.1, 21 which was also seen in our population. The cause of this inter-gender difference remains unknown. We show that higher levels of hsTnI predict the secondary outcome in men but not in women with HFpEF. This is in accordance with the concept of the importance of sex in HF. If novel biomarkers are to be implemented clinically to stratify HF patients by risk, sex differences warrant careful consideration.
Limited numbers of patients, particularly when the population was stratified by HF type, such as in the HFpEF group, and also by sex represent a limitation of the current study. The large difference in sample size between the two main HF groups (HFrEF and HFpEF) means that the results regarding the HFpEF group, especially when stratified by sex, must be interpreted cautiously. Our population has a high proportion of HFrEF patients compared with other cohort studies. 22 However, the relative prevalences of HFpEF and HFrEF vary widely among studies and other large cohorts have shown higher prevalences of HFrEF than HFpEF. 23 In addition, our population is relatively young in comparison with other cohorts. Increased age is associated more strongly with HFpEF than HFrEF. Our cohort also included a low proportion of women, who accounted for only 32.2% of the total population. Again, HFpEF is more likely to affect women than men. This may explain why the present cohort includes a high proportion of HFrEF patients in comparison with HFpEF patients. Further sex-specific studies and studies with more diverse populations and larger populations of HFpEF and HFmrEF patients are required in order to validate our findings.
In composite outcome was better for both hs troponin assays in HFpEF than in HFrEF, but the strongest performance in HFpEF appeared to be from hsTnT. The potential prognostic role for hs troponin assays in HFpEF has a sex-specific aspect, whereby the more sensitive hsTnI assay is a better predictor of outcome in men than in women. Our results highlight the need to investigate novel biomarkers in HF with due consideration to both ventricular phenotype and sex.
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